AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025

13.10.2025 01:31:00 CEST | Business Wire | Press Release

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025.

The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC).

This will be the first presentation of clinical data from a 212Pb-PSMA therapy at a major oncology conference – an important milestone in advancing targeted alpha therapies for prostate cancer and a clear demonstration of AdvanCell’s leadership in radioligand therapy. The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with metastatic prostate cancer.

The abstract is available online on the ESMO website (link), and features data as of a May 9, 2025 cut-off. The poster to be presented at ESMO will include updated safety and efficacy data and additional treatment cohorts.

Details of the abstract and presentation:

Results from the Phase 1b Dose Escalation of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TheraPb Trial

Presenter: Aaron Hansen, MD, BSc, MBBS, FRACP, Princess Alexandra Hospital, Brisbane, Australia
Presentation Number: 2388P
Session: Prostate Cancer Poster Session
Session Time/ Place: Saturday, October 18 / 12:00-12:45 PM CET / Hall 25
Poster Display Time: 9:00 AM – 5:00 PM CET

About the TheraPb trial

The TheraPb trial (NCT05720130) is a prospective, open-label Phase 1/2 dose-escalation and expansion study designed to determine the safety and tolerability of escalating doses of 212Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) during the dose-finding Phase 1b. The Phase 2 expansion will assess the efficacy and safety of 212Pb-ADVC001 at the recommended Phase 2 doses across three indications. The trial incorporates randomization and dose optimization elements to rigorously evaluate optimal dosing strategies of 212Pb-ADVC001 in PSMA-positive mCRPC and in hormone-sensitive prostate cancer (mHSPC).

About 212Pb-ADVC001

212Pb-ADVC001 is a novel, proprietary and patented small molecule PSMA-targeting radioligand with optimized physicochemical properties labelled with 212Pb, an alpha-emitting payload (radionuclide) with a high dose rate, short half-life (10.6 hours) and simple decay scheme. 212Pb-ADVC001 is designed to deliver radiation at a cellular level to more effectively kill prostate cancer cells while minimizing toxicity.

About AdvanCell

AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing capabilities, cutting-edge science and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally.

For more information, visit www.advancell.com.au and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013316172/en/

Contacts

Andrew Adamovich, CEO
contact@advancell.com.au

For media inquiries, please contact:
MEDiSTRAVA
Mark Swallow, Frazer Hall, Sylvie Berrebi
advancell@medistrava.com
+44 (0)20 3928 6700

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 16:00:00 CEST | Press Release

TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device. A live view of the device. The real device's screen opens in its own window on the developer's lapto

Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 16:00:00 CEST | Press Release

Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor

METI and GX Acceleration Agency will hold GGX Finance Summit 202616.10.2026 15:00:00 CEST | Press Release

On Monday, October 26th, the Ministry of Economy, Trade and Industry (METI) and GX Acceleration Agency will hold the GGX (Global GX) Finance Summit at Tokyo Prince Hotel and online. The Summit will advance discussions on transition finance, industry decarbonization, and the role of business and finance in driving decarbonization. It will also promote cooperation among government, industry, and the financial sector, and lead international rulemaking toward achieving both emission reductions and economic growth. Outline of GGX Finance Summit Date: October 26th, 2026 10:00 - 16:20 (JST, GMT+9:00) Venue: Tokyo Prince Hotel (Tokyo) (3-3-1 Shiba-Koen, Minato-ku, Tokyo 105-8560, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: GX Future Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation) Press Registration Please complete your registration by accessing the official

Dubai Culture: Dubai Ranks First Globally in Attracting New FDI Projects in Cultural and Creative Industries in 202516.10.2026 13:32:00 CEST | Press Release

Dubai Culture and Arts Authority has revealed that Dubai retained its position as the world’s leading destination for new foreign direct investment (FDI) projects in the cultural and creative industries (CCIs) in 2025, ranking first globally for the fourth consecutive year. According to data from the Financial Times’ fDi Markets, a leading source of greenfield FDI intelligence, Dubai topped the ranking of 233 cities, ahead of London, Singapore, Riyadh and Bengaluru. The results reflect the strength of the emirate’s investment environment and its appeal to creative businesses, investors, entrepreneurs and talent from around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016681830/en/ Dubai Culture: Dubai ranks first globally in attracting new FDI projects in cultural and creative industries in 2025 (Graphic: AETOSWire) In 2025, Dubai attracted 754 new projects in the cultural and creative industries, with greenf

Horizon3 and Pax8 Expand Partnership to Bring Autonomous Security Testing to MSPs Across Europe16.10.2026 08:03:00 CEST | Press Release

Horizon3, the AI-Native Proactive Security Company, today announced the expansion of its Pax8 partnership across Europe, bringing the NodeZero® Proactive Security Platform to the region’s managed service providers (MSPs) through the Pax8 Marketplace. The expansion enables partners to build recurring security services that help small and midsized businesses understand how attackers could compromise their environments, prioritize corrective actions, and verify remediation. Building on the companies’ North American marketplace launch, the European expansion makes autonomous offensive security testing accessible to more MSPs and the businesses they protect. Partners can use NodeZero to deliver initial assessments, support remediation engagements, and establish ongoing testing programs without conducting every penetration test manually. “MSPs are accountable for protecting their customers’ security, but a list of vulnerabilities does not tell them what is actually exploitable, and their lev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom